Blood trails: nanotechnology-enabled biomarker quantification for early disease detection

Dr. Tony Hu’s research focuses on developing and validating integrated nanotechnique-based strategies for marker discovery and molecular diagnostics in peripheral blood samples to provide a translatable solution for personalized medicine. His innovations aim to fill current gaps in early detection, real-time therapy monitoring and effective prognostics. Instead of competing on lowering the detection limit of those known markers with poor specificity on disease diagnosis, Hu’s focus is to utilize nanotech-induced capabilities to discover those unknowns and to address major unsolved problems in oncology and infectious diseases.

Dr. Tony (Ye) Hu PhD,  is an Associate Professor at the Biodesign Institute at Arizona State University’s Virginia G. Piper Center for Personalized Diagnostics and at ASU’s School of Biological and Health Systems Engineering.  Dr. Hu’s research focuses on developing and validating integrated nanotechnique-based strategies for marker discovery and molecular diagnostics in peripheral blood samples to provide a translatable solution for personalized medicine. His innovations aim to fill current gaps in early detection, real-time therapy monitoring and effective prognostics. He has assembled a diverse team with backgrounds in biochemistry, mass spectrometry, nanofabrication, and biomedical engineering to answer these needs.  Dr. Hu received his Ph.D. in Biomedical Engineering from the University of Texas at Austin where he focused on developing nanomaterials as biosensors for disease diagnosis. He has published more than 50 journal articles and has received five U.S. patents (issued and pending) on these subjects since his first faculty appointment in 2011.